Floatz logo

AD5 (E1-, E2B-)-HER2/NEU VACCINE ETBX-021

Colorectal Cancer Metastatic

ImmunityBio, Inc.vaccinePhase 1/2Dormant
D
25/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
12/ 100
Competitive Position
65/ 100

Competitive context

65 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Inno-206
Northwell Health
Phase 4B
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Centre Georges Francois Leclerc
Phase 2B

View all 50 →

Same molecule, other indications

AD5 (E1-, E2B-)-HER2/NEU VACCINE ETBX-021 is also rated in:

malignant pancreatic neoplasmDormant
D
Indicative ·
30 / 100
View asset →
non-small cell lung carcinomaDormant
D
Indicative ·
24 / 100
View asset →
ovarian cancerDormant
D
Indicative ·
24 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →